Prise en charge des carcinomes ovariens de haut grade séreux et/ou endométrioïdes de stades avancés (III-IV) et testing HRD-BRCA en 2023: actualisation selon les données publiées et/ou présentées en 2022

Frédéric Selle; Florence Joly; Laurence Gladieff; Karine Prulhière; Alexandra Leary; Elsa Kalbacher; Etienne Rouleau; Isabelle Ray-Coquard

doi:10.1016/S0007-4551(23)00329-6

Prise en charge des carcinomes ovariens de haut grade séreux et/ou endométrioïdes de stades avancés (III-IV) et testing HRD-BRCA en 2023: actualisation selon les données publiées et/ou présentées en 2022

Frédéric Selle, Florence Joly, Laurence Gladieff, Karine Prulhière, Alexandra Leary, Elsa Kalbacher, Etienne Rouleau, Isabelle Ray-Coquard

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

2 Citations (Scopus)

Résumé

Management of high grade, serous and/or endometrioid, advanced (stages III-IV) ovarian carcinomas and HRD-BRCA testing in 2023: update according to data published/presented in 2022 Molecular analysis of ovarian carcinomas must be now systematically performed to determine BRCA1 and BRCA2 status as well as genomic instability score. Several types of tests are available. From a clinical perspective, new data from phase III clinical trials presented in 2022 confirm the key role of PARP inhibitors in first-line medical treatment of high-grade serous ovarian cancers. A new algorithm that includes all new evidence is proposed for selection of first-line therapy.

Titre traduit de la contribution	Management of high grade, serous and/or endometrioid, advanced (stages III-IV) ovarian carcinomas and HRD-BRCA testing in 2023: Update according to data published/presented in 2022
langue originale	Français
Pages (de - à)	6S5-6S9
journal	Bulletin du Cancer
Volume	110
Numéro de publication	6
Les DOIs	https://doi.org/10.1016/S0007-4551(23)00329-6
état	Publié - 1 juin 2023

mots-clés

BRCA status
Genomic instability score
High grade advanced
Molecular analysis
PARP inhibitors
ovarian cancer

Accès au document

10.1016/S0007-4551(23)00329-6

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Selle, F., Joly, F., Gladieff, L., Prulhière, K., Leary, A., Kalbacher, E., Rouleau, E., & Ray-Coquard, I. (2023). Prise en charge des carcinomes ovariens de haut grade séreux et/ou endométrioïdes de stades avancés (III-IV) et testing HRD-BRCA en 2023: actualisation selon les données publiées et/ou présentées en 2022. Bulletin du Cancer, 110(6), 6S5-6S9. https://doi.org/10.1016/S0007-4551(23)00329-6

@article{7dd9f810807a49b886b87401a88f31a8,

title = "Prise en charge des carcinomes ovariens de haut grade s{\'e}reux et/ou endom{\'e}trio{\"i}des de stades avanc{\'e}s (III-IV) et testing HRD-BRCA en 2023: actualisation selon les donn{\'e}es publi{\'e}es et/ou pr{\'e}sent{\'e}es en 2022",

abstract = "Management of high grade, serous and/or endometrioid, advanced (stages III-IV) ovarian carcinomas and HRD-BRCA testing in 2023: update according to data published/presented in 2022 Molecular analysis of ovarian carcinomas must be now systematically performed to determine BRCA1 and BRCA2 status as well as genomic instability score. Several types of tests are available. From a clinical perspective, new data from phase III clinical trials presented in 2022 confirm the key role of PARP inhibitors in first-line medical treatment of high-grade serous ovarian cancers. A new algorithm that includes all new evidence is proposed for selection of first-line therapy.",

keywords = "BRCA status, Genomic instability score, High grade advanced, Molecular analysis, PARP inhibitors, ovarian cancer",

author = "Fr{\'e}d{\'e}ric Selle and Florence Joly and Laurence Gladieff and Karine Prulhi{\`e}re and Alexandra Leary and Elsa Kalbacher and Etienne Rouleau and Isabelle Ray-Coquard",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Masson SAS. Tous droits r{\'e}serv{\'e}s.",

year = "2023",

month = jun,

day = "1",

doi = "10.1016/S0007-4551(23)00329-6",

language = "Fran{\c c}ais",

volume = "110",

pages = "6S5--6S9",

journal = "Bulletin du Cancer",

issn = "0007-4551",

number = "6",

}

Selle, F, Joly, F, Gladieff, L, Prulhière, K, Leary, A, Kalbacher, E, Rouleau, E & Ray-Coquard, I 2023, 'Prise en charge des carcinomes ovariens de haut grade séreux et/ou endométrioïdes de stades avancés (III-IV) et testing HRD-BRCA en 2023: actualisation selon les données publiées et/ou présentées en 2022', Bulletin du Cancer, VOL. 110, Numéro 6, p. 6S5-6S9. https://doi.org/10.1016/S0007-4551(23)00329-6

Prise en charge des carcinomes ovariens de haut grade séreux et/ou endométrioïdes de stades avancés (III-IV) et testing HRD-BRCA en 2023: actualisation selon les données publiées et/ou présentées en 2022. / Selle, Frédéric; Joly, Florence; Gladieff, Laurence et al.
Dans: Bulletin du Cancer, Vol 110, Numéro 6, 01.06.2023, p. 6S5-6S9.

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

TY - JOUR

T1 - Prise en charge des carcinomes ovariens de haut grade séreux et/ou endométrioïdes de stades avancés (III-IV) et testing HRD-BRCA en 2023

T2 - actualisation selon les données publiées et/ou présentées en 2022

AU - Selle, Frédéric

AU - Joly, Florence

AU - Gladieff, Laurence

AU - Prulhière, Karine

AU - Leary, Alexandra

AU - Kalbacher, Elsa

AU - Rouleau, Etienne

AU - Ray-Coquard, Isabelle

PY - 2023/6/1

Y1 - 2023/6/1

N2 - Management of high grade, serous and/or endometrioid, advanced (stages III-IV) ovarian carcinomas and HRD-BRCA testing in 2023: update according to data published/presented in 2022 Molecular analysis of ovarian carcinomas must be now systematically performed to determine BRCA1 and BRCA2 status as well as genomic instability score. Several types of tests are available. From a clinical perspective, new data from phase III clinical trials presented in 2022 confirm the key role of PARP inhibitors in first-line medical treatment of high-grade serous ovarian cancers. A new algorithm that includes all new evidence is proposed for selection of first-line therapy.

AB - Management of high grade, serous and/or endometrioid, advanced (stages III-IV) ovarian carcinomas and HRD-BRCA testing in 2023: update according to data published/presented in 2022 Molecular analysis of ovarian carcinomas must be now systematically performed to determine BRCA1 and BRCA2 status as well as genomic instability score. Several types of tests are available. From a clinical perspective, new data from phase III clinical trials presented in 2022 confirm the key role of PARP inhibitors in first-line medical treatment of high-grade serous ovarian cancers. A new algorithm that includes all new evidence is proposed for selection of first-line therapy.

KW - BRCA status

KW - Genomic instability score

KW - High grade advanced

KW - Molecular analysis

KW - PARP inhibitors

KW - ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=85167397468&partnerID=8YFLogxK

U2 - 10.1016/S0007-4551(23)00329-6

DO - 10.1016/S0007-4551(23)00329-6

M3 - Article

C2 - 37573039

AN - SCOPUS:85167397468

SN - 0007-4551

VL - 110

SP - 6S5-6S9

JO - Bulletin du Cancer

JF - Bulletin du Cancer

IS - 6

ER -